创新药盘中走强，创新药ETF国泰（517110）涨超2%，如何捕捉创新药新一轮成长红利？

Core Viewpoint - The innovative drug sector is experiencing a strong rally, with significant growth potential driven by global business development (BD) authorizations and advanced technology platforms [3][4]. Group 1: Industry Trends - The innovative drug market is expected to see continuous BD authorizations, which are crucial for driving the next wave of growth and revenue [3]. - Advanced technology platforms such as ADC, bispecific antibodies, and CAR-T are leading the innovation in the post-PD-1 era, positioning Chinese innovative drug companies at the forefront globally [3]. - China is leading in the ADC field, with a significant number of reports presented at ASCO, indicating a strong presence in the global market [3]. - The bispecific antibody pipeline in China accounts for nearly 50% of the global pipeline, with impressive clinical data and a projected 14 products expected to enter international markets in 2024, surpassing $10 billion in total transaction value [3]. Group 2: Upcoming Events and Opportunities - Key industry conferences such as WCLC and ESMO are anticipated to showcase the latest clinical research from Chinese innovative drug companies, serving as potential catalysts for the sector [4]. - High-demand disease areas, including weight loss and autoimmune diseases, present significant unmet clinical needs, offering expansive future market opportunities [4]. - Policy support, including optimization of medical insurance access and the introduction of new categories, is crucial for the continued growth of the innovative drug sector [4]. Group 3: Investment Strategies - The innovative drug sector is viewed as a long-term investment opportunity, with public funds gradually recovering after previous declines [5]. - Investors are encouraged to adopt a strategy of buying on dips, particularly focusing on the innovative drug ETF from Guotai (517110), which provides a balanced exposure to major innovative drug companies across A-shares and Hong Kong stocks [5]. - Notable companies in the innovative drug space include Heng Rui Medicine, King’s Ray Biotechnology, BeiGene, and others, which are recommended for consideration [5].